CNS Summit Releases Annual CNS Summit Innovation Index


BOCA RATON, Fla., Nov. 22, 2022 (GLOBE NEWSWIRE) — Released at the CNS Summit in Boca Raton, FL, the CNS Summit Innovation Index, developed in conjunction with IDEA Pharma, evaluates innovation in three dimensions:

  • Innovation in clinical development that can foster sustained, long-term growth through the use of new technologies and clinical trial optimization, including through remote patient monitoring and digitally-streamlined clinical trials
  • Commercial partnerships and operations, such as investing in next-generation infrastructure to optimize and realize manufacturing aspirations
  • Investment in digital technologies and partnerships including with academic institutes and using incubators and competitions to discover new avenues for growth at the earliest stages

Companies must have a strong balance between these ingredients. That was a key factor for the 2022 top trio of Roche, Bayer, and Pfizer. The scope of Roche’s commercial mHealth investments and high-tech infrastructure, as well as its multi-pronged foray into the digital realm, moved Roche up several rungs from last year to the top of the list.

Bayer’s intensive incubator approach and artificial intelligence and deep learning research earned it the number two spot on this year’s index. Pfizer, last year’s Innovation Index winner, ranked third this year by further growing digital innovation foundations. Other top-ranking firms, including Boehringer Ingelheim, Eli Lilly, and Merck KGaA traversed multiple avenues of resource innovation.

CNS Summit’s Chief Curator and Chairman, Amir Kalali, said, “The CNS Summit has been at the forefront of recognizing digital and R&D innovation, and we’re delighted to celebrate such strong leadership in these areas.”

IDEA Pharma’s CEO, Mike Rea, added, “There’s an important distinction between invention and innovation – companies need to be great at both to bring great medicines to patients. This is an industry built on a thousand innovations, and it is important to recognize and celebrate those companies that can connect new possibilities to patient value.”


For thirteen years, CNS Summit has been reimagining clinical development: driving collaboration, promoting innovation, and fostering novel technologies in our ongoing mission to accelerate the success of programs bringing novel treatments to patients.

CNS Summit is a community working collaboratively to shape the future of the life sciences. The CNS Summit 2023 will take place November 8-11, 2023 in Boston, MA. For more information, visit

For further information please contact:

Media Contact:

Glenn Silver
Lazar – Finn Partners
[email protected]
646 871 8485